Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Aug 3, 2026 (2 months ago)

Clobetasol Propionate Cream USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed content uniformity specifications.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Clobetasol Propionate Cream USP, 0.05%, 60 g tube, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Pithampur (MP) 454 775, INDIA, NDC 68180-956-04.

Affected NDC 68180-0956-04

Compare with the code on your package — it is the most precise check available.

Drug: Clobetasol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Clobetasol Propionate
NDC 68180-0956
.5 mg/g Cream
Topical
Lupin Pharmaceuticals, Inc. Rx
Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-956-04
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0789-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Clobetasol recalls

See all
Class II · Moderate risk

Clobetasol Propionate Lotion 0.05%

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Terminated Stability / shelf life Preferred Pharmaceuticals, Inc. NDC 68788-7768-01 D-0768-2022

Other recalls by Lupin Pharmaceuticals Inc.

All 2026 recalls
Class II · Moderate risk

Ganirelix Acetate Injection

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Ongoing Impurity / degradation Lupin Pharmaceuticals Inc. NDC 70748-274-01 D-0220-2026